GLP-1 receptor agonists and incretin-based therapies have rapidly reshaped the landscape of obesity and metabolic care, generating widespread interest across healthcare, policy, and the public. As use expands, clinicians are navigating new questions about patient eligibility, medical indications, treatment algorithms, movement and exercise, body composition, pricing models, and insurance coverage-while patients encounter a fast-moving mix of media attention, evolving evidence, and changing policy.

This interactive fireside chat will bring together experts from obesity medicine, exercise science, research, and health policy to explore the most current and emerging topics surrounding GLP-1 and incretin-based therapies. Moderated by Dr. Nina Crowley, PhD, RDN, the discussion will examine real-world clinical decision-making, including which patients may benefit most from treatment, how clinicians approach eligibility and coverage considerations, and emerging practices such as microdosing.

Panelists will also discuss movement and exercise recommendations, body composition changes during treatment, and how to assess and communicate these changes using meaningful, patient-centered metrics. In addition, the panel will explore the evolving policy landscape affecting access to care, including Medicare and Medicaid coverage, pricing models, and legislation such as the Treat and Reduce Obesity Act.

Rather than a traditional slide-based lecture, this session will be structured as a moderated conversation designed to incorporate emerging developments and audience questions, providing practical insights to support thoughtful patient care and informed clinical decision-making.